Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
CTMX Stock Chart & Stats
$5.54
-$0.06(-5.83%)
At close: 4:00 PM EST
$5.54
-$0.06(-5.83%)
Day’s Range― - ―
52-Week Range$0.40 - $6.15
Previous CloseN/A
Volume1.08M
Average Volume (3M)2.96M
Market Cap
$909.87M
Enterprise Value$911.78M
Total Cash (Recent Filing)$143.63M
Total Debt (Recent Filing)$5.60M
Price to Earnings (P/E)13.7
Beta2.76
Next Earnings
Mar 04, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding169,435,400
10 Day Avg. Volume3,414,339
30 Day Avg. Volume2,960,132
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-190.73
Price to Sales (P/S)0.63
P/FCF Ratio-1.00
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue8.02
Enterprise Value/Gross Profit8.02
Enterprise Value/Ebitda34.90
Forecast
1Y Price Target
$9.00Price Target Upside62.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy MomentumAnalyst highlights strong early efficacy momentum from the CX-2051 Phase 1 trial, where confirmed tumor responses and durable progression benefit already exceed standard late-line benchmarks and could drive a meaningful stock re-rating if maintained.
Enrollment And Dose-response SignalExpanded enrollment and a dose-dependent response signal, with the trial aiming to enroll around one hundred patients and higher-dose cohorts showing notably higher response rates, should provide clearer evidence for efficacy and dosing strategy.
Key Opinion Leader Support And Regulatory PathwayKey opinion leader endorsements and a clearly articulated registrational pathway using overall survival as the primary endpoint could support regulatory approval prospects and broaden commercial potential if tolerability remains manageable.
Bears Say
Analyst Caution And De-risking RequirementAnalyst neutrality driven by the need for additional de-risking data highlights the risk that a weaker efficacy readout would confine the therapy to a small salvage indication rather than a broad late-line disruptor.
Serious Adverse Event DisclosureDisclosure of a treatment-related fatal acute kidney injury raises safety concerns that could increase regulatory scrutiny and weigh on investor confidence.
Tolerability-driven Commercial LimitationPersistent high rates of severe diarrhea would likely limit commercial adoption to narrow salvage use and materially reduce the drug's market opportunity.
CytomX Therapeutics News
CTMX FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
CytomX Therapeutics Inc lowest stock price was $0.40 and its highest was $6.15 in the past 12 months.
What is CytomX Therapeutics Inc’s market cap?
CytomX Therapeutics Inc’s market cap is $909.87M.
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is Mar 04, 2026 which is in 39 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.049 by -$0.041.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does CytomX Therapeutics Inc have?
CytomX Therapeutics Inc has 169,435,400 shares outstanding.
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.049. Following the earnings report the stock price went down -13.604%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Currently, no hedge funds are holding shares in CTMX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CytomX Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (62.45% Upside)
$9.00 (62.45% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 443.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
583.39%
12-Months-Change
Fundamentals
Return on Equity
66.76%
Trailing 12-Months
Asset Growth
13.87%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CTMX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive overall sentiment with strong clinical progress and strategic advancements in key programs, despite a decrease in revenue and some adverse events in trials.View all CTMX earnings summariesCTMX Stock 12 Month Forecast
Average Price Target
$9.00
▲(62.45% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Verastem
―
Arcturus Therapeutics
―
KalVista Pharmaceuticals
―
Bicycle Therapeutics
―
Ownership Overview
1.09% Insiders
15.10% Mutual Funds
0.35% Other Institutional Investors
74.83% Public Companies and Individual Investors